Incidence of advanced prostate cancer in men under the age of 50 in the United States: A population-based study 1973-2010
Clouded in the murkiness of the debate surrounding the use of the PSA test is an increasing escalation of younger men (under the age of 50 years) being diagnosed with advanced prostate cancer. We know [...]
Efficacy of Combined Androgen Blockade with Zoledronic Acid *
It is known that Zoledronic acid (ZA) reduces the risk of developing skeletal-related events (SRE) which are caused by bone metastasis in prostate cancer (PCa). ZA also improves the quality of life (QOL). ZA has [...]
Study Shows That The Immune Responses Is Enhanced and Sustained When Provenge Is Given After Androgen Deprivation Therapy in Biochemically-Recurrent Prostate Cancer
Last April there was some preliminary data from the long-term Phase II STAND study presented at 29th Annual European Association of Urology (EAU) Congress that showed that sipuleucel-T (Provenge) when given after the start of [...]
Bone Metastases and Prostate Cancer
The vast majority of men with advanced prostate cancer will eventually develop bone metastases. Given this fact it is important to understand what is meant by the term bone metastases. Bones serve as the supporting [...]
Complementary and Alternative Medicine with Chemotherapy
The following was written and posted by Paul Edwards to the Advanced Prostate Cancer Online Support Group: The March 2014 issue of the Asia-Pacific Journal of Clinical Oncology published an article “Why do some cancer patients [...]
Can Chemotherapy (Docetaxel) Be Enhanced By Zoledronic Acid Pretreatment in Resistant Prostate Cancer Cells *
Docetaxel is the only globally approved first-line chemotherapy for the treatment of castrate resistant prostate cancer. Yhe universal truth is that all men taking docetaxel will become refractory to the treatment. Zoledronic acid (ZA) is [...]